Furthermore, adiponectin treatment more effectively induced RANKL expression and inhibited OPG expression in primary osteoblasts from AIS patients than in those from control groups, suggesting that high plasma adiponectin levels may affect a low bone mass through increases of RANKL/OPG ratio in osteoblasts. This evidence concerns the gene TNFRSF11B and androgen insensitivity syndrome.